Numinus Archives

Psychedelics News

Numinus

Press Releases

13 May 2021

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

Experienced executives fill senior roles in business development, M&A, clinic operations and design, and corporate communications VANCOUVER, BC, May 13, 2021 /CNW/ – Numinus Wellness Inc....

By Microdose

Press Releases

11 May 2021

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial VANCOUVER, BC, May 11, 2021 /CNW/ - Numinus Wellness Inc....

By Microdose

Press Releases

10 May 2021

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada VANCOUVER, May 10, 2021 /CNW/ – Numinus Wellness Inc....

By Microdose

Press Releases

29 Apr 2021

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS…

Events subsequent to quarter end include $40....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

19 Mar 2021

Numinus Announces Closing of $40-Million Bought Deal Financing

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, March...

By Microdose

Press Releases

9 Mar 2021

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services, accelerates IP development and increases psychedelic supply capacity VANCOUVER, BC, March 9, 2021 /CNW/ – Numinus Wellness Inc....

By Microdose

Press Releases

4 Mar 2021

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds VANCOUVER, BC, March 4, 2021 /CNW/ - Numinus Wellness Inc....

By Microdose

Press Releases

2 Mar 2021

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage VANCOUVER, BC, March 2, 2021 /CNW/ - Numinus Wellness Inc....

By Microdose

Press Releases

18 Feb 2021

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb....

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result